Litton Talks Talazoparib in BRCA1/2+ Advanced Breast Cancer
Jennifer Litton, MD, discusses findings from the phase 3 EMBRACA trial on talazoparib in patients with advanced BRCA1/2-positive breast cancer.
Related Articles
Fruquintinib Receives Positive EU CHMP Opinion for Previously Treated mCRC
CHMP has voiced its support for the approval of fruquintinib in previously treated metastatic colorectal cancer.
Navigating Personalized Approaches With Radiation Therapy for Early-Stage Breast Cancer
Robert W. Mutter, MD, discusses personalized treatment approaches with radiation and endocrine therapy with
DENALI Study Seeks to Prove Efficacy of Azenosertib in High-Grade Serous Ovarian Cancer
The phase 2 DENALI trial is investigating azenosertib in patients with high-grade serous ovarian cancer.
European Medicines Agency Grants Orphan Drug Designation to Annamycin in AML
The European Medicines Agency has granted orphan drug designation to annamycin for the treatment of patients with acute myeloid leukemia.
Richardson Discusses Implications of the FDA Withdrawal of Melflufen in Multiple Myeloma
Paul G. Richardson, MD, speaks on the FDA’s decision to withdraw the approval of melflufen plus dexamethasone in multiple myeloma.
FDA Approves Lumisight and Lumicell DVS for Residual Breast Cancer Detection
The FDA has approved the optical imaging agent Lumisight and the Lumicell Direct Visualization System for use in fluorescence imaging in breast cancer.
Personalized Dosimetry With Y-90 Glass Microspheres Shows Positive Activity in HCC
Etienne Garin, MD, PhD, details how the PROACTIF study was conducted and how Y-90 Glass Microspheres could fill an unmet need for patients with hepatocellular…
Sinno Spotlights Key Clinical Trials Driving Targeted Approaches in Gynecologic Oncology
Abdulrahman Sinno, MD, highlights key trials that have impacted the treatment paradigm in endometrial and ovarian cancer throughout 2023.
Zanubrutinib Associated With Longer Treatment Persistence, Duration, and TTD in Real-World MCL
Real-world treatment with zanubrutinib was linked to longer treatment persistence, duration, and time to discontinuation in mantle cell lymphoma.
ROSALIE Trial of EO2401/Nivolumab/Bevacizumab in Recurrent Glioblastoma Concludes
The database of the phase 1/2 trial of EO2401 in combination with nivolumab with or without bevacizumab in recurrent glioblastoma has locked.